All In Biotech

NDA 209387 · Exela Pharma

Nipride Rtu In Sodium Chloride 0.9%

Sodium Nitroprusside · Intravenous

Last checked: Nov 20, 2026Latest source record: Jul 13, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Mar 8, 2017

Approved uses

1

Original approval plus efficacy supplements

Registered trials

68

4 Phase 3, 9 recruiting

FAERS reports

387

360 serious, 85 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: (A) EXCESSIVE HYPOTENSION; (B) CYANIDE TOXICITY (A) EXCESSIVE HYPOTENSION: Sodium Nitroprusside can cause precipitous decreases in blood pressure which can lead to irreversible ischemic injuries or death. Use only with continuous blood pressure monitoring [see Dosage and Administration ( 2.2 ) and Warnings and Precautions ( 5.1 ). (B) CYANIDE TOXICITY: Sodium nitroprusside metabolism produces dose-related cyanide, which can be lethal. A patient’s ability to buffer cyanide will be exceeded in less than one hour at the maximum dose rate (10 mcg/kg/min); limit infusions at the maximum rate to as short a duration as possible [see Warnings and Precautions ( 5.2 )]. WARNING: (A) EXCESSIVE HYPOTENSION; (B) CYANIDE TOXICITY (A) Sodium Nitroprusside can cause precipitous decreases in blood pressure which can lead to irreversible ischemic injuries or death. Use only with continuous blood...

What it is approved for

From the label in effect Jul 20, 2018.

Sodium nitroprusside is a direct acting vasodilator indicated for: • Immediate reduction of blood pressure ( 1.1 ) • Producing controlled hypotension to reduce bleeding during surgery. ( 1.2 ) • Treatment of acute heart failure to reduce left ventricular end-diastolic pressure, pulmonary capillary wedge pressure, peripheral vascular resistance and mean arterial blood pressure. ( 1.3 ) 1.1 Immediate Reduction of Blood Pressure Sodium nitroprusside is indicated for the immediate reduction of blood pressure of adult and pediatric patients in hypertensive crises. 1.2 Induction and Maintenance of Controlled Hypotension Sodium nitroprusside indicated for induction and maintenance of controlled hypotension in adults and children during surgery, to reduce bleeding. 1.3 Treatment of Acute Heart Failure Sodium nitroprusside is indicated for the treatment of acute heart failure to reduce, left ventricular end-diastolic pressure, pulmonary capillary wedge pressure, peripheral vascular resistance and mean arterial blood pressure.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 8, 2017 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
3 products under this application
  • NIPRIDE RTU IN SODIUM CHLORIDE 0.9% · SODIUM NITROPRUSSIDE 20MG/100ML (0.2MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
  • NIPRIDE RTU IN SODIUM CHLORIDE 0.9% · SODIUM NITROPRUSSIDE 50MG/100ML (0.5MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
  • NIPRIDE RTU IN SODIUM CHLORIDE 0.9% · SODIUM NITROPRUSSIDE 10MG/50ML (0.2MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · SOLUTION, INTRAVENOUS · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Nitroprusside" as an intervention, any sponsor and status, largest first.

All 68 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • renal failure74
  • pain62
  • injury59
  • anxiety58
  • unevaluable event55
  • drug ineffective53
  • fear53
  • toxicity to various agents49
  • renal injury44
  • emotional distress43
  • anhedonia41
  • renal impairment38

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20048
20056
200610
20076
20086
20098
201010
201175
20129
20133
20141
201516
20168
201715
201811
201920
202019
202129
202227
202327
202431
202519
202623

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,077 on PubMed

Sponsor: Exela Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.